To the Editor: For patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase, a complete cytogenetic response at 12 months is widely accepted as an optimal response.¹ This response was used as a primary end point in the trial of ...

To the Editor: Khor et al. (June 3 issue)¹ show that variants of the cytokine-inducible SRC homology 2 (SH2) domain protein (CISH) gene are associated with susceptibility to diverse infections and suggest that negative regulators of cytokine signaling ...

To the Editor: Zuckerman et al. (July 1 issue)¹ support the status quo regarding geographic differences in Medicare payment, asking policymakers to “resist the appeal of simple solutions.” Yet they, themselves, take the easy road by simply relying upon ...

To the Editor: Reproductive medicine continually confronts new ethical frontiers, as illustrated by a recently published case (July 15 issue).¹ Although similar cases with men and sperm retrieval have been observed, posthumous oocyte retrieval is new.

...

To the Editor: The Accreditation Council for Graduate Medical Education (ACGME) is to be applauded for its response to the 2008 Institute of Medicine (IOM) report and the process of soliciting input from stakeholder organizations to prepare the new ...

To the Editor: Vincenzi et al. (July 22 issue)¹ report on the off-label use of the antiemetic agent aprepitant in the management of pruritus in patients with cancer who are receiving erlotinib. Erlotinib is an oral drug that is incompletely absorbed (...

To the Editor: Over the past year, we have observed three instances in which patients with advanced cancer received blood products solely for the purpose of altering a laboratory value to satisfy eligibility criteria for clinical trials of new ...